Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMIT: selumetinib plus dacarbazine versus placebo plus dacarbazine in metastatic uveal melanoma
NL-OMON44683Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intraocular melanoma, eye melanoma and choroidal melanoma comparing Selumetinib + dacarbazine with Placebo + dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Apr 2014; status: recruiting.
02
Drugs
selumetinibdacarbazine
03
Conditions
intraocular melanomaeye melanomachoroidal melanoma
Beyond the preview
Go deeper on NL-OMON44683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44683.